The National Pharmaceutical Council (NPC) in a recent study published in JAMA suggests including productivity in value assessments can have a noticeable impact.
Taruja Karmarkar, NPC/Duke-Margolis health policy fellow, discusses the study in a blog post published on NPC.
“We found that productivity is often included in assessments of value, but usually included as a sensitivity, or secondary, analysis, not immediately visible to payers who may refer to VAF reports to inform coverage decisions,” she writes. “When productivity is not included, the value of a health intervention is often underestimated.”
To read the blog post, click here.